Skip to main content

Amgen EVENITY revenue

  • AMGN · Nasdaq
  • Biotechnology
  • S&P 500
$465.67−0.30%Close 13 Nov 2026 · Market value $253.3B

EVENITY revenue at Amgen came to $751.0M for the quarter to 30 Sep 2026, up 38.8% from a year earlier.

As Amgen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 4 Nov 2026.

By quarter

$318.0MDec 2023$342.0MMar 2024$391.0MJun 2024$399.0MSep 2024$431.0MDec 2024$442.0MMar 2025$518.0MJun 2025$541.0MSep 2025$599.0MDec 2025$562.0MMar 2026$714.0MJun 2026$751.0MSep 2026
Amgen EVENITY revenue, every reported period
Period endingEVENITY revenueChange on a yearFiled
30 Sep 2026$751.0Mup 38.8%4 Nov 2026
30 Jun 2026$714.0Mup 37.8%5 Aug 2026
31 Mar 2026$562.0Mup 27.1%1 May 2026
31 Dec 2025$599.0Mup 39.0%13 Feb 2026
30 Sep 2025$541.0Mup 35.6%5 Nov 2025
30 Jun 2025$518.0Mup 32.5%6 Aug 2025
31 Mar 2025$442.0Mup 29.2%2 May 2025
31 Dec 2024$431.0Mup 35.5%14 Feb 2025
30 Sep 2024$399.0Mup 30.0%31 Oct 2024
30 Jun 2024$391.0Mup 39.1%7 Aug 2024
31 Mar 2024$342.0Mup 34.6%3 May 2024
31 Dec 2023$318.0Mup 41.3%14 Feb 2024
30 Sep 2023$307.0Mup 52.7%31 Oct 2023
30 Jun 2023$281.0Mup 47.1%4 Aug 2023
31 Mar 2023$254.0Mup 49.4%28 Apr 2023
31 Dec 2022$225.0M—9 Feb 2023
30 Sep 2022$201.0M—4 Nov 2022
30 Jun 2022$191.0M—5 Aug 2022
31 Mar 2022$170.0M—28 Apr 2022

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Amgen: Product sales · Repatha revenue · Prolia revenue · ENBREL revenue · TEZSPIRE revenue · TEPEZZA revenue · BLINCYTO revenue · Otezla revenue · Nplate revenue · UPLIZNA revenue · KRYSTEXXA revenue · IMDELLTRA/IMDYLLTRA revenue · Vectibix revenue · KYPROLIS revenue · Aranesp revenue · XGEVA revenue · United States revenue · ROW revenue · financial statements

Every KPI and segment of AMGN, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.